Sutro Biopharma, Inc. (STRO)
15.34
-0.14
(-0.90%)
USD |
NASDAQ |
Sep 18, 16:00
15.32
-0.02
(-0.13%)
Pre-Market: 20:00
Sutro Biopharma Enterprise Value : 339.78M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 339.78M |
| September 17, 2026 | 342.10M |
| September 16, 2026 | 344.09M |
| September 15, 2026 | 360.00M |
| September 14, 2026 | 365.80M |
| September 11, 2026 | 364.98M |
| September 10, 2026 | 381.05M |
| September 09, 2026 | 389.76M |
| September 08, 2026 | 402.11M |
| September 04, 2026 | 418.19M |
| September 03, 2026 | 425.98M |
| September 02, 2026 | 424.82M |
| September 01, 2026 | 430.62M |
| August 31, 2026 | 421.00M |
| August 28, 2026 | 424.48M |
| August 27, 2026 | 438.74M |
| August 26, 2026 | 440.73M |
| August 25, 2026 | 440.89M |
| August 24, 2026 | 425.15M |
| August 21, 2026 | 434.26M |
| August 20, 2026 | 436.25M |
| August 19, 2026 | 448.69M |
| August 18, 2026 | 450.84M |
| August 17, 2026 | 454.82M |
| August 14, 2026 | 424.98M |
| Date | Value |
|---|---|
| August 13, 2026 | 438.74M |
| August 12, 2026 | 438.57M |
| August 11, 2026 | 500.57M |
| August 10, 2026 | 508.69M |
| August 07, 2026 | 506.20M |
| August 06, 2026 | 485.82M |
| August 05, 2026 | 501.56M |
| August 04, 2026 | 511.01M |
| August 03, 2026 | 501.56M |
| July 31, 2026 | 486.15M |
| July 30, 2026 | 496.92M |
| July 29, 2026 | 472.06M |
| July 28, 2026 | 478.85M |
| July 27, 2026 | 483.50M |
| July 24, 2026 | 464.76M |
| July 23, 2026 | 476.70M |
| July 22, 2026 | 473.38M |
| July 21, 2026 | 466.75M |
| July 20, 2026 | 459.96M |
| July 17, 2026 | 476.20M |
| July 16, 2026 | 478.85M |
| July 15, 2026 | 516.48M |
| July 14, 2026 | 516.98M |
| July 13, 2026 | 546.98M |
| July 10, 2026 | 578.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Upstream Bio, Inc. | 32.12M |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.53M |
| Revenue (Quarterly) | 9.839M |
| Total Expenses (Quarterly) | 48.37M |
| EPS Diluted (Quarterly) | -2.325 |
| Gross Profit Margin (Quarterly) | 87.17% |
| Profit Margin (Quarterly) | -391.6% |
| Earnings Yield | -113.5% |
| Normalized Earnings Yield | -105.97 |